MarketInOut Stock Screener Log In | Sign Up
 

Freenome Inc

NASDAQ • Healthcare • Diagnostics & Research • Quote as of 10/19/2026 16:00
Freenome Inc stock price and volume chart

Company Profile

IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,262.5 mln
Float76.17 mln

Piotroski F-Score

2 / 9
Weak

Relative Strength

10 / 100
Significantly lagging

ROE

-0.89
Negative

ROA

-0.84
Negative

Business Description

Freenome is a California-based company working to make cancer detection simpler and less invasive through blood tests. Rather than relying on traditional screening methods, the company uses advanced computing and biological analysis to identify early signs of cancer from a single blood draw. Its tests cover a wide range of cancers, including colorectal, lung, breast, and pancreatic, among others. Founded in 2014, Freenome aims to give patients and doctors a faster, easier way to catch cancer before it becomes harder to treat.

Key Fundamentals

EPS-2.04
ROE-0.89
RPS1.33
ROIC-4.81
ROA-0.84
EBITDA, mln-0.76
EV / EBITDA-2,271
EV / EBIT-2,271
Revenue, mln35.41
EV / Revenue80.08

Quote Details

Last 12.57
Change 0.82 (6.98%)
Open 11.93
Volume 645,847
Turnover 8,118,296
Average Volume 680,115

Financial Ratios

Current Ratio0.21
Price / Book2.11
Price / Tangible Book2.11

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio3.68

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -4.92% 30 / 100   
1 Month -26.53% 12 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog